Combined photodynamic therapy and hyperbaric oxygenation in carcinoma of the esophagus and the esophago-gastric junction✩

Maier, Andrea B.; Tomaselli, Florian; Anegg, Udo; Rehak, Peter; Fell, B.; Luznik, S.; Pintér, H; Smolle‐Jüttner, Freyja Maria

doi:10.1016/s1010-7940(00)00592-3

Cited by 49 publications

(45 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meta-analysis was not possible due to heterogeneity between the trials. All trials reported morbidity results, seven reported on mortality [113][114][115][116][117][118][119] and four reported on QoL outcomes. [115][116][117][118] Only two of the studies reported resource use, both in terms of days of hospitalisation.…”

Section: Results Of Effectiveness (Palliative Intent)mentioning

confidence: 99%

“…115,116 The comparison of HpD and ALA found no significant differences in Karnofsky status scores (44% vs 23%, p = 0.12).…”

Section: Quality Of Lifementioning

confidence: 90%

“…115,116 Dysphagia scores were significantly reduced in the PDT-plus-HBO group in only one trial. 116 Stenosis length decreased overall, between 5 and 6 mm, but these changes were not significantly different between groups.…”

Section: Morbiditymentioning

confidence: 96%

“…[107][108][109][110][111][112][113][114][115][116][117][118][119] Three studies were available only as abstracts, 107,110,111 the rest were published as full papers. In a small number of trials, the presented data did not appear to entirely support the authors' conclusions; this has been indicated in the data extraction tables.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…110 Eight studies reported on palliative PDT treatments for oesophageal cancer, four RCTs 112-114,119 and four non-randomised comparative trials. [115][116][117][118] Participants in six studies were diagnosed with advanced oesophageal cancer, and overall most trials included only patients who were not eligible for resection due to anatomical restrictions, poor health or refusal. Comparators in these trials included chemotherapy, radiotherapy, neodymium-doped yttrium aluminium garnet (Nd:YAG) laser or PDT.…”

Section: Study Characteristicsmentioning

confidence: 99%

See 4 more Smart Citations

A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett’s oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin

Fayter

Corbett²,

Heirs³

et al. 2010

Health Technol Assess

126

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of project...

show abstract

Section: Results Of Effectiveness (Palliative Intent)mentioning

confidence: 99%

“…115,116 The comparison of HpD and ALA found no significant differences in Karnofsky status scores (44% vs 23%, p = 0.12).…”

Section: Quality Of Lifementioning

confidence: 90%

Section: Morbiditymentioning

confidence: 96%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

See 3 more Smart Citations

A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett’s oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin

Fayter

Corbett²,

Heirs³

et al. 2010

Health Technol Assess

126

View full text Add to dashboard Cite

show abstract

Perfluorocarbon‐Loaded and Redox‐Activatable Photosensitizing Agent with Oxygen Supply for Enhancement of Fluorescence/Photoacoustic Imaging Guided Tumor Photodynamic Therapy

Zhong

Wang

et al. 2019

Adv Funct Materials

140

View full text Add to dashboard Cite

The wide clinical application of photodynamic therapy (PDT) is hampered by poor water solubility, low tumor selectivity, and nonspecific activation of photosensitizers, as well as tumor hypoxia which is common for most solid tumors. To overcome these limitations, tumor-targeting, redox-activatable, and oxygen self-enriched theranostic nanoparticles are developed by synthesizing chlorin e6 (Ce6) conjugated hyaluronic acid (HA) with reducible disulfide bonds (HSC) and encapsulating perfluorohexane (PFH) within the nanoparticles (PFH@HSC). The fluorescence and phototoxicity of PFH@HSC nanoparticles are greatly inhibited by a self-quenching effect in an aqueous environment. However, after accumulating in tumors through passive and active tumor-targeting, PFH@HSC appear to be activated from "OFF" to "ON" in photoactivity by the redox-responsive destruction of the vehicle's structure. In addition, PFH@HSC can load oxygen within lungs during blood circulation, and the oxygen dissolved in PFH is slowly released and diffuses over the entire tumor, finally resulting in remarkable tumor hypoxia relief and enhancement of PDT efficacy by generating more singlet oxygen. Taking advantage of the excellent imaging performance of Ce6, the tumor accumulation of PFH@HSC can be monitored by fluorescent and photoacoustic imaging after intravenous administration into tumor-bearing mice. This PFH@HSC nanoparticle might have good potential for dual imaging-guided PDT in hypoxic solid tumor treatment.

show abstract

Hyperbaric Oxygen‐Facilitated Cancer Treatment: A Minireview

Li,

Zhang,

2024

Advanced NanoBiomed Research

View full text Add to dashboard Cite

Hypoxia in malignant tumors is a major factor in inducing the failure of clinical cancer treatment. Although several strategies have been developed to relieve hypoxia, most are still in the preclinical research phase. Therefore, hyperbaric oxygen (HBO), an approved adjuvant therapy for alleviating hypoxia clinically, is an excellent choice for enhancing the efficacy of cancer treatment that is impeded by tumor hypoxia. In this minireview, recent advances in HBO‐facilitated cancer treatment, including clinical applications and nanomedicine‐mediated cancer therapy are introduced. At the end of this minireview, the potential challenges faced by HBO therapy before clinical use are discussed. It is hoped that this review will provide a reference for future clinical research on the application of HBO in cancer treatment.

show abstract

Combined photodynamic therapy and hyperbaric oxygenation in carcinoma of the esophagus and the esophago-gastric junction✩

Abstract: According to this prospective non-randomized study, combined PDT/HBO represents a new approach in the treatment of esophageal and cardia cancer which appears to have enhanced the efficiency of PDT.

Cited by 49 publications

References 13 publications

A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett’s oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin

A systematic review of photodynamic therapy in the treatment of pre-cancerous skin conditions, Barrett’s oesophagus and cancers of the biliary tract, brain, head and neck, lung, oesophagus and skin

Perfluorocarbon‐Loaded and Redox‐Activatable Photosensitizing Agent with Oxygen Supply for Enhancement of Fluorescence/Photoacoustic Imaging Guided Tumor Photodynamic Therapy

Hyperbaric Oxygen‐Facilitated Cancer Treatment: A Minireview

Contact Info

Product

Resources

About